Blue Water Biotech Inc

BWV

$

Closing

1D

YTD

Market cap

$

52 week high

$

52 week low

$

Volume

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

Market cap

$

Analysts' Rating

HOLD

Price Target (Mean)

-

Total Analysts

1

P/E

Operating Margin

0.00%

Beta

Revenue Growth (Annual)

0.00%

52 week high

$

52 week low

$

Div. Yield

%

EPS Annual Growth

-27.91

Note on Purification and Zakat

  • Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly). 
  • If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
  • For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them. 

Company Profile

Blue Water Biotech, Inc., formerly Blue Water Vaccines Inc., is a biotechnology company. The Company is focused on developing transformational therapies to address significant health challenges globally. The Company is engaged in developing a streptococcus pneumonia vaccine candidate, designed to specifically prevent highly infectious middle ear infections, known as acute otitis media (AOM), in children, and prevention of pneumonia in the elderly. The Company is also developing a universal flu vaccine that provides protection from all virulent strains in addition to licensing a norovirus (NoV) shell and protrusion (S&P) nanoparticle versatile virus-like particle (VLP) vaccine platform from Cincinnati Children’s Hospital Medical Center to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, among others. In addition, the Company is developing a Chlamydia vaccine candidate with the University of Texas Health Science Center in San Antonio (UT Health).